We are people, patients, parents, caregivers, researchers… Together, we are Sanofi, a healthcare organization dedicated to improving the lives of people worldwide.
Aligning on Market Needs
In 2018, we changed the organizational structure of two of our Global Business Units (GBUs) to refocus our operations on the specific needs of both mature and emerging markets. Our new Primary Care and China & Emerging Markets GBUs have been operating since the start of 2019.
Speciality Care - Sanofi Genzyme
Sanofi Genzyme brings together our Rare Diseases, Multiple Sclerosis, Oncology, Immunology, and Rare Blood Disorder franchises, with this guiding principle: develop innovative treatments to help people with complex and debilitating diseases.
Three major launches in 2018
- Dupixent® (dupilumab) was launched in the United States for patients with moderate-to-severe asthma. This is the second indication for Dupixent®, which is already available in nearly 20 countries for adults with moderate-to-severe atopic dermatitis.
- We also launched Libtayo® (cemiplimab), the first and only treatment approved in the United States for cutaneous squamous cell carcinoma, the second most common skin cancer.
- Cablivi® (caplacizumab), derived from the Ablynx research platform, became the first treatment to be approved in Europe and the United States for acquired thrombotic thrombocytopenic purpura, a rare blood clotting disorder. Cablivi® extends our new Rare Blood Disorder franchise, which also includes Eloctate® and Alprolix®.
Vaccines - Sanofi Pasteur
Sanofi Pasteur is a world leader in vaccines, producing over a billion doses every year to immunize more than 500 million people across the globe against a number of diseases.
The world’s leading producer of influenza vaccines, Sanofi Pasteur’s 2018 successes included its age-differentiated range of influenza vaccines in the United States and the launch of a quadrivalent vaccine in Europe.
Our Consumer Healthcare business unit provides consumer-centric self-care solutions in four categories: Digestive Health, Pain Care, Nutritional Health, and Cough and Cold, Allergy. Sanofi is ranked third in the global market and first in Europe and Latin America. As a result of our growth model strategy, we are currently number one in Digestive Health, number two in Pain Care, number three in Nutritional Health, and number four in Cough and Cold, Allergy.
Our new Primary Care GBU focuses exclusively on mature markets (the United States, Canada, Europe, Japan, South Korea, Australia and New Zealand). Drawing on the strengths of our Diabetes & Cardiovascular and Established Products franchises, this entity brings together healthcare professionals and a diversified portfolio of treatments to raise the standard of care and better serve patients’ needs.
China & Emerging Markets
This new GBU focuses on the substantial growth potential of China and emerging markets, and includes Established Products, Diabetes & Cardiovascular, and Specialty Care in these regions. From the start, Sanofi has worked to provide better access to healthcare in all parts of the world, developing medical treatments adapted for each market. Today, Sanofi is the world leader in emerging markets.
We are also the third largest international pharmaceutical company in China, which is now our second biggest market globally, after the United States.